12,372 trials
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 39.4; 43.3 Percentage of participants
Vaginal Infection
Primary: Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit — 47; 18 Participants — p=<0.001
Vaginal Infection
Primary: Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit — 47; 25 Participants — p=0.002
Malaria, Vivax
Primary: Percentage of Participants With Relapse-free Efficacy at Six Months After Administration of Tafenoquine With DHA-PQP and DHA-PQP Alone — 12; 22 Percentage of…
Cardiovascular Disease
Primary: Number of Subjects With Major Adverse Cardiovascular Events — 170; 167 participants — p=0.91
Infantile Spasms
Primary: Number of Participants With Severe Treatment-emergent Adverse Events (TEAEs) — 6 Participants
Infantile Spasms
Primary: Number of Participants With Severe Treatment-emergent Adverse Events (TEAEs) — 7 Participants
Pain Associated With Fibromyalgia
Primary: Average Daily Pain Score (ADPS) for DS-5565 — 4.77; 5.58; 7.08; 7.38 score on a scale
Cariostatic Agents · Mouthwashes
Primary: Change in Streptococcus Mutans Levels in Dental Plaque — 3.11; 0.93; 1.91; 2.23 log10CFU/g — p=0.123
Healthy Volunteers
Primary: Energy Expenditure — 1.37; 1.40; 1.28; 1.27 kcal/min — p=0.0001
Contraception
Primary: Number of Subjects With Pregnancy Outcomes to Measure Contraceptive Efficacy — 100 Participants
Cholestasis · Cholestasis of Parenteral Nutrition
Primary: Number of Participant With Decrease in Direct Bilirubin Level — 2; 0 Participants
Influenza, Human
Primary: Immunogenicity Endpoint: The Geometric Mean Titer (GMT) and GMT Ratio for the Four Strains Included in the Vaccine, Non-inferiority Analysis. — 65.01; NA; NA; 75.16…
Asthma
Primary: Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus QMF149 at Week 26 — 2.050; 2.029; 1.984; 1.953 litre (L) — p=<0.001
Constipation - Functional
Primary: Number of Participants Classified as Overall Responders at Week 12 — 76; 28 Participants — p=0.1609